Skip to content
Big Changes in AML Care as Targeted Therapy Options Expand episode artwork

Oct 20, 2025 11 min

Big Changes in AML Care as Targeted Therapy Options Expand

from Oncology News Central Peer-Spectives Hosted by Oncololgy News Central

Options for the treatment of acute myeloid leukemia (AML) are rapidly expanding, says Amir Fathi, MD, associate professor of medicine at Harvard Medical School in Boston and program director of the Center for Leukemia at Massachusetts General Hospital. “Over the course of the last 10 to 12 years, there have been a series of approvals, predominantly for targeted therapies,” he explains. Speaking with Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology, Dr. Fathi outlines how and when to look for mutations in AML and key considerations for various targeted therapies. He also shares what developments he is anticipating. “I’m most excited about where we’re moving in the upfront setting.” Dr. Fathi reported various financial relationships. Dr. Figlin reported various financial relationships.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Big Changes in AML Care as Targeted Therapy Options Expand

0:00 11:09

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of Oncology News Central Peer-Spectives?

This episode is 11 minutes long.

When was this Oncology News Central Peer-Spectives episode published?

This episode was published on October 20, 2025.

Can I download this Oncology News Central Peer-Spectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.